Physician profile
Michael P Moran
NPI 1063442515
$2,446.36
in general payments reported to CMS, 2019-2025
20 companies · $502 in 2025
The $502 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $130 · 2021: $375 · 2022: $84.56 · 2023: $710 · 2024: $332 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,545.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $380.70 | 2021-2025 | |
| Micro-Tech Endoscopy USA, INC. | $348.59 | 2021-2024 | Lesion Hunter, Biopsy Forceps, Sureclip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.55 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $283.06 | 2019-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $212.04 | 2022-2024 | Dupixent |
| Ardelyx, INC. | $201.71 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $124.95 | 2023-2025 | |
| Pfizer INC. | $124.04 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $84.69 | 2019-2023 | Ocaliva |
| Gilead Sciences, INC. | $75.31 | 2019 | |
| Boston Scientific Corporation | $59.91 | 2020-2023 | Orcapod, Captivator II |
| Janssen Biotech, INC. | $46.02 | 2024-2025 | Simponi Aria, Stelara, Simponi |
| Qol Medical, LLC | $39.24 | 2025 | Sucraid |
| Novo Nordisk INC | $33.53 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $31.78 | 2023 | Sutab |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $26.63 | 2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $21.10 | 2021 | |
| Amgen INC. | $13.80 | 2025 | Uplizna |
| Shire North American Group INC | $12.83 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.